{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:47:05Z","timestamp":1790657225131,"version":"4.1.0"},"reference-count":252,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022416","name":"Center for Drug Evaluation and Research","doi-asserted-by":"publisher","award":["FDA 1R01FD008168\u201001A1"],"award-info":[{"award-number":["FDA 1R01FD008168\u201001A1"]}],"id":[{"id":"10.13039\/100022416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NCI P30 CA016520"],"award-info":[{"award-number":["NCI P30 CA016520"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Diffuse large B\u2010cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R\u2010CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola\u2010R\u2010CHP and R\u2010CHOP, whereas elderly or frail\/unfit patients may be treated with R\u2010mini\u2010CHOP or palliation. Frontline trials aim to improve outcomes for patients with high\u2010risk disease utilizing R\u2010CHOP\u2009+\u2009novel agents, CAR\u2010T, and bispecific antibodies. Trials in the elderly\/unfit population are minimizing and omitting chemotherapy. Risk\u2010adapted approaches targeting cell of origin (COO) and utilizing interim PET imaging or ctDNA to guide therapy escalation or deescalation remain under investigation. Second line therapy curative\u2010intent approaches include CAR\u2010T or autologous stem cell transplantation, depending upon timing of disease progression after first\u2010line therapy. In the relapsed\/refractory setting, there has been a rapid growth in the therapeutic armamentarium, including bispecific antibody combinations with chemotherapy, bispecific antibodies with antibody\u2010drug conjugates, and brentuximab vedotin\u2009+\u2009lenalidomide\u2009+\u2009rituximab. Multiple novel trials are further advancing the field away from chemotherapy including targeted therapy\u2010antibody combinations, new bispecific antibodies and bispecific antibody combinations, immunomodulatory agents, and cellular therapy. In this review, we summarize recent data and discuss ongoing efforts to improve the management of DLBCL.<\/jats:p>","DOI":"10.1002\/ajh.70229","type":"journal-article","created":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:29:56Z","timestamp":1770510596000},"page":"832-863","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["2026 Update on the Management of Diffuse Large B\u2010Cell Lymphoma"],"prefix":"10.1002","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8895-1625","authenticated-orcid":false,"given":"Elise A.","family":"Chong","sequence":"first","affiliation":[{"name":"Lymphoma Program, Abramson Cancer Center Perelman School of Medicine at the University of Pennsylvania  Philadelphia Pennsylvania USA"},{"name":"Division of Hematology\/Oncology Hospital of the University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-8738","authenticated-orcid":false,"given":"Emily B.","family":"Tomasulo","sequence":"additional","affiliation":[{"name":"Lymphoma Program, Abramson Cancer Center Perelman School of Medicine at the University of Pennsylvania  Philadelphia Pennsylvania USA"},{"name":"Division of Hematology\/Oncology Hospital of the University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-5271","authenticated-orcid":false,"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[{"name":"Lymphoma Program, Abramson Cancer Center Perelman School of Medicine at the University of Pennsylvania  Philadelphia Pennsylvania USA"},{"name":"Division of Hematology\/Oncology Hospital of the University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_2_12_3_1","volume-title":"WHO Classification of Tumours Haematolymphoid Tumours: Volume 11. Part A + Part B","year":"2024"},{"key":"e_1_2_12_4_1","unstructured":"\u201cDiffuse Large B\u2010Cell Lymphoma\u2014Cancer Stat Facts \u201dSEER accessed January 1 2026 https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html."},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010022\u201001620\u20102"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12254\u2010024\u201001002\u20107"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185\u2010024\u201003781\u20105"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26151"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/35000501"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102003\u201005\u20101545"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000843"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25666"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqaa185"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath\u20102017\u2010204548"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201012\u2010322362"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.2383"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.3660"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102011\u201004\u2010345256"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u2010473"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201001\u2010643569"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102009\u201003\u2010212191"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102009\u201005\u2010220095"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01583"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002600"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00743"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102015\u201005\u2010647602"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6262"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43556\u2010025\u201000346\u20108"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010190316"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010023\u201000827\u20105"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010019\u20100691\u20106"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.3.815"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3479"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.0985"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102012\u201006\u2010435842"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.4342"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2740"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001727"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801445"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010018\u20100016\u20108"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.015"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025652"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2493"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102013\u201009\u2010524108"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002729"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u2010470"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010187350"},{"key":"e_1_2_12_50_1","unstructured":"\u201cRecommendations for Initial Evaluation Staging and Response Assessment of Hodgkin and Non\u2010Hodgkin Lymphoma: The Lugano Classification | Journal of Clinical Oncology \u201daccessed January 2 2026 https:\/\/ascopubs.org\/doi\/full\/10.1200\/JCO.2013.54.8800."},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.9846"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003526"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003277"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8093"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.142752"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.5246"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41587\u2010021\u201000981\u2010w"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(15)70106\u20103"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14311"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00377"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.01.321"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016332"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006415"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201001712"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201001534"},{"key":"e_1_2_12_67_1","unstructured":"NCCN \u201cGuidelines Detail \u201daccessed January 2 2026 https:\/\/www.nccn.org\/guidelines\/guidelines\u2010detail?category=1&id=1480."},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282573"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70110_LBA4"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2025.02.007"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.0765"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.5866"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807023390104"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.4582"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.6929"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201007\u2010793984"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(19)33008\u20109"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00999"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000875"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010023\u201000971\u2010y"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013998"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u2010471"},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(13)60313\u2010X"},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(12)70481\u20103"},{"key":"e_1_2_12_87_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010020\u201000900\u20107"},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01994"},{"key":"e_1_2_12_89_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02403"},{"key":"e_1_2_12_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002567"},{"key":"e_1_2_12_91_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201000925"},{"key":"e_1_2_12_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.10.006"},{"key":"e_1_2_12_93_1","unstructured":"E.Cliff \u201cThe Predictive Value of Cell\u2010Of\u2010Origin Subtype by Hans Algorithm in 718 Patients With Large B Cell Lymphoma Receiving Polatuzumab Vedotin \u201dIn: ASH; 2024 accessed January 2 2026 https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper202153.html."},{"key":"e_1_2_12_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70094_289"},{"key":"e_1_2_12_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010178623"},{"key":"e_1_2_12_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12982"},{"key":"e_1_2_12_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.05.016"},{"key":"e_1_2_12_98_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286168"},{"key":"e_1_2_12_99_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf085"},{"key":"e_1_2_12_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010200746"},{"key":"e_1_2_12_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010018\u20100320\u20109"},{"key":"e_1_2_12_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.06.013"},{"key":"e_1_2_12_103_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26068"},{"key":"e_1_2_12_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16875"},{"key":"e_1_2_12_105_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201000481"},{"key":"e_1_2_12_106_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010194000"},{"key":"e_1_2_12_107_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014907"},{"key":"e_1_2_12_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u20101955"},{"key":"e_1_2_12_109_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010198023"},{"key":"e_1_2_12_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u201065"},{"key":"e_1_2_12_111_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01375"},{"key":"e_1_2_12_112_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01366"},{"key":"e_1_2_12_113_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020637"},{"key":"e_1_2_12_114_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010155995"},{"key":"e_1_2_12_115_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010022\u201005333\u20105"},{"key":"e_1_2_12_116_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3163_90"},{"key":"e_1_2_12_117_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u2010476"},{"key":"e_1_2_12_118_1","unstructured":"Celgene \u201cA Phase 3 Multicenter Randomized Double\u2010Blind Placebo\u2010Controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R\u2010CHOP Chemotherapy vs Placebo Plus R\u2010CHOP Chemotherapy in Participants With Previously Untreated High\u2010Risk Large B\u2010Cell Lymphoma (GOLSEEK\u20101) \u201dClinicaltrials.gov; 2025 accessed January 2 2026 https:\/\/clinicaltrials.gov\/study\/NCT06356129."},{"key":"e_1_2_12_119_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u2010477"},{"key":"e_1_2_12_120_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010022\u201001731\u20104"},{"key":"e_1_2_12_121_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027347"},{"key":"e_1_2_12_122_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000975996.32786.92"},{"key":"e_1_2_12_123_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u2010670"},{"key":"e_1_2_12_124_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.CD\u201022\u20101276"},{"key":"e_1_2_12_125_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u20105459"},{"key":"e_1_2_12_126_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.164_2880"},{"key":"e_1_2_12_127_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u2010475"},{"key":"e_1_2_12_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.870"},{"key":"e_1_2_12_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.09.004"},{"key":"e_1_2_12_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.08.005"},{"key":"e_1_2_12_131_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392\u2010023\u201001358\u2010y"},{"key":"e_1_2_12_132_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70093_OT05"},{"key":"e_1_2_12_133_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2025000741"},{"key":"e_1_2_12_134_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.050617"},{"key":"e_1_2_12_135_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102567.2007.02555.x"},{"key":"e_1_2_12_136_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1474\u20109726.2008.00443.x"},{"key":"e_1_2_12_137_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008239"},{"key":"e_1_2_12_138_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"e_1_2_12_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(11)70069\u20109"},{"key":"e_1_2_12_140_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02666"},{"key":"e_1_2_12_141_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27151"},{"key":"e_1_2_12_142_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004665"},{"key":"e_1_2_12_143_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281407"},{"key":"e_1_2_12_144_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102003\u201006\u20102095"},{"key":"e_1_2_12_145_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201007\u2010259333"},{"key":"e_1_2_12_146_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278719"},{"key":"e_1_2_12_147_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2450091"},{"key":"e_1_2_12_148_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.7442"},{"key":"e_1_2_12_149_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02465"},{"key":"e_1_2_12_150_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000758"},{"key":"e_1_2_12_151_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16743"},{"key":"e_1_2_12_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2021.10.003"},{"key":"e_1_2_12_153_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010199685"},{"key":"e_1_2_12_154_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967820.91359.ec"},{"key":"e_1_2_12_155_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u201064"},{"key":"e_1_2_12_156_1","unstructured":"\u201cOptimizing Frontline Therapy for Diffuse Large B Cell Lymphoma (DLBCL) in Older Adults: A Glofitamab\u2010Based Response\u2010Adapted Window\u2010Style Study (GLORY)\u2014ASCO \u201daccessed January 2 2026 https:\/\/www.asco.org\/abstracts\u2010presentations\/252456."},{"key":"e_1_2_12_157_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u201062"},{"key":"e_1_2_12_158_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u201063"},{"key":"e_1_2_12_159_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u201061"},{"key":"e_1_2_12_160_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028649"},{"key":"e_1_2_12_161_1","unstructured":"Z.Weili \u201cThe Efficacy and Safety of Zanubrutinib Rituximab and Lenalidomide (ZR2) Versus Rituximab Combined With Low\u2010Dose CHOP (R\u2010miniCHOP) in the Treatment of Unfit or Frail De Novo Diffuse Large B\u2010Cell Lymphoma Patients Aged Older Than or Equal to 70\u2009Years: A Multicenter Prospective Randomized Open\u2010Label Controlled Trial. Clinicaltrials.gov; 2023 \u201daccessed January 2 2026 https:\/\/clinicaltrials.gov\/study\/NCT05179733."},{"key":"e_1_2_12_162_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010174769"},{"key":"e_1_2_12_163_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1975188"},{"key":"e_1_2_12_164_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022348"},{"key":"e_1_2_12_165_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021672"},{"key":"e_1_2_12_166_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19455"},{"key":"e_1_2_12_167_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_2_12_168_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301665"},{"key":"e_1_2_12_169_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018730"},{"key":"e_1_2_12_170_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201000399"},{"key":"e_1_2_12_171_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u20103710"},{"key":"e_1_2_12_172_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(21)00375\u20102"},{"key":"e_1_2_12_173_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596"},{"key":"e_1_2_12_174_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2030164"},{"key":"e_1_2_12_175_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016504"},{"key":"e_1_2_12_176_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018893"},{"key":"e_1_2_12_177_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010023\u201002572\u20105"},{"key":"e_1_2_12_178_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015262"},{"key":"e_1_2_12_179_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573\u2010023\u201000807\u20101"},{"key":"e_1_2_12_180_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016945"},{"key":"e_1_2_12_181_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008240"},{"key":"e_1_2_12_182_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725"},{"key":"e_1_2_12_183_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010173951"},{"key":"e_1_2_12_184_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010199155"},{"key":"e_1_2_12_185_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009260"},{"key":"e_1_2_12_186_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(22)00335\u20107"},{"key":"e_1_2_12_187_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013640"},{"key":"e_1_2_12_188_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010023\u201002726\u20105"},{"key":"e_1_2_12_189_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201001957"},{"key":"e_1_2_12_190_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004155"},{"key":"e_1_2_12_191_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(24)00746\u20103"},{"key":"e_1_2_12_192_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010198544"},{"key":"e_1_2_12_193_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u2010667"},{"key":"e_1_2_12_194_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u2010268"},{"key":"e_1_2_12_195_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u2010668"},{"key":"e_1_2_12_196_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010208539"},{"key":"e_1_2_12_197_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010021\u201001436\u20100"},{"key":"e_1_2_12_198_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018598"},{"key":"e_1_2_12_199_1","unstructured":"Inc MG \u201cA Global Phase 1B Study of JNJ\u201090014496 A CD19\/CD20 BI\u2010Specific\u2026 by Matthew Ku \u201daccessed January 5 2026 https:\/\/library.ehaweb.org\/eha\/2025\/eha2025\u2010congress\/4159316\/matthew.ku.a.global.phase.1b.study.of.jnj\u201090014496.a.cd19.cd20.bi\u2010specific.html."},{"key":"e_1_2_12_200_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408771"},{"key":"e_1_2_12_201_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010023\u201002785\u20108"},{"key":"e_1_2_12_202_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018\u2010025\u201000940\u20103"},{"key":"e_1_2_12_203_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010198684"},{"key":"e_1_2_12_204_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(24)02462\u20100"},{"key":"e_1_2_12_205_1","doi-asserted-by":"crossref","unstructured":"B.Hu L. J.Nastoupil H.Holmes et\u00a0al. \u201cA CRISPR\u2010Edited Allogeneic Anti\u2010CD19 CAR\u2010T Cell Therapy With a PD\u20101 Knockout (CB\u2010010) in Patients With Relapsed\/Refractory B Cell Non\u2010Hodgkin Lymphoma (r\/r B\u2010NHL): Updated Phase 1 Results From the ANTLER Trial. JCO \u201d2024;42(16_suppl):7025\u20107025 https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.7025.","DOI":"10.1200\/JCO.2024.42.16_suppl.7025"},{"key":"e_1_2_12_206_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_12_207_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013289"},{"key":"e_1_2_12_208_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007939"},{"key":"e_1_2_12_209_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010024\u201001084\u2010w"},{"key":"e_1_2_12_210_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010024\u201002410\u20108"},{"key":"e_1_2_12_211_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913"},{"key":"e_1_2_12_212_1","doi-asserted-by":"crossref","unstructured":"J. M.Vose C. Y.Cheah M. R.Clausen et\u00a0al. \u201c3\u2010Year Update From the Epcore NHL\u20101 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B\u2010Cell Lymphoma. Blood 2024;144(Supplement 1):4480 \u201dhttps:\/\/doi.org\/10.1182\/blood\u20102024\u2010198714.","DOI":"10.1182\/blood-2024-198714"},{"key":"e_1_2_12_213_1","doi-asserted-by":"crossref","unstructured":"M. J.Dickinson C.Carlo\u2010Stella F.Morschhauser et\u00a0al. \u201cFixed\u2010Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed or Refractory Large B\u2010Cell Lymphoma: 3\u2010Year Follow\u2010Up From a Pivotal Phase II Study. Blood 2024;144(Supplement 1):865 \u201dhttps:\/\/doi.org\/10.1182\/blood\u20102024\u2010194333.","DOI":"10.1182\/blood-2024-194333"},{"key":"e_1_2_12_214_1","doi-asserted-by":"crossref","unstructured":"Y.Karimi C.Cheah J.Vose et\u00a0al. \u201cSustained Remissions Beyond 4\u2009Years With Epcoritamab Monotherapy: Long Term Follow\u2010Up Results From the Pivotal EPCORE NHL\u20101 Trial in Patients With Relapsed or Refractory Large B\u2010Cell Lymphoma. Blood 2025;146(Supplement 1):5513 \u201dhttps:\/\/doi.org\/10.1182\/blood\u20102025\u20105513.","DOI":"10.1182\/blood-2025-5513"},{"key":"e_1_2_12_215_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029117"},{"key":"e_1_2_12_216_1","doi-asserted-by":"crossref","unstructured":"S.Gaballa J. Z.Hou S.Devata et\u00a0al. \u201cEvaluation of AZD0486 a Novel CD19xCD3 T\u2010Cell Engager in Relapsed\/Refractory Diffuse Large B\u2010Cell Lymphoma in an Ongoing First\u2010In\u2010Human Phase 1 Study: High Complete Responses Seen in CAR\u2010T\u2010Naive and CAR\u2010T\u2010Exposed Patients. Blood 2024;144(Supplement 1):868 \u201dhttps:\/\/doi.org\/10.1182\/blood\u20102024\u2010193681.","DOI":"10.1182\/blood-2024-193681"},{"key":"e_1_2_12_217_1","doi-asserted-by":"crossref","unstructured":"K.Patel J.Crombie T.Phillips et\u00a0al. \u201cA First\u2010In\u2010Human Phase 1 Trial of LY4152199 a B\u2010Cell Activation Factor Receptor (BAFF\u2010R) T\u2010Cell Engager Bispecific Antibody in Patients With Previously Treated B\u2010Cell Malignancies (BAF_FRontier\u20101 Trial in Progress). Blood 2025;146(Supplement 1):5524 \u201dhttps:\/\/doi.org\/10.1182\/blood\u20102025\u20105524.","DOI":"10.1182\/blood-2025-5524"},{"key":"e_1_2_12_218_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(24)01774\u20104"},{"key":"e_1_2_12_219_1","unstructured":"\u201cFood and Drug Administration Center for Drug Evaluation and Research. Oncologic Drugs Advisory Committee (ODAC) Meeting Morning Session Tuesday May 20 2025. Published Online May 20 2025 \u201daccessed December 18 2025 https:\/\/www.fda.gov\/media\/187746\/download."},{"key":"e_1_2_12_220_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026830"},{"key":"e_1_2_12_221_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u20103736"},{"key":"e_1_2_12_222_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010194581"},{"key":"e_1_2_12_223_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201000992"},{"key":"e_1_2_12_224_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70093_78"},{"key":"e_1_2_12_225_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015719"},{"key":"e_1_2_12_226_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024526"},{"key":"e_1_2_12_227_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172"},{"key":"e_1_2_12_228_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005794"},{"key":"e_1_2_12_229_1","unstructured":"M.Matasar Z. M.Li T. P.Vassilakopoulos et\u00a0al. \u201c(S101) POLATUZUMAB VEDOTIN RITUXIMAB GEMCITABINE AND OXALIPLATIN (POLA\u2010R\u2010GEMOX) FOR RELAPSED\/REFRACTORY (R\/R) DIFFUSE LARGE B\u2010CELL LYMPHOMA (DLBCL): RESULTS FROM THE RANDOMIZED PHASE III POLARGO TRIAL.\u201d"},{"key":"e_1_2_12_230_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(21)00139\u2010X"},{"key":"e_1_2_12_231_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283459"},{"key":"e_1_2_12_232_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7097"},{"key":"e_1_2_12_233_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201024\u201002242"},{"key":"e_1_2_12_234_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(20)30225\u20104"},{"key":"e_1_2_12_235_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283480"},{"key":"e_1_2_12_236_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70253"},{"key":"e_1_2_12_237_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018905"},{"key":"e_1_2_12_238_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1986219"},{"key":"e_1_2_12_239_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1992622"},{"key":"e_1_2_12_240_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(20)30120\u20104"},{"key":"e_1_2_12_241_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-202789"},{"key":"e_1_2_12_242_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401532"},{"key":"e_1_2_12_243_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70094_316"},{"key":"e_1_2_12_244_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-480"},{"key":"e_1_2_12_245_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-479"},{"key":"e_1_2_12_246_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-193167"},{"key":"e_1_2_12_247_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201003\u2010276246"},{"key":"e_1_2_12_248_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.8.2685"},{"key":"e_1_2_12_249_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_12_250_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020854"},{"key":"e_1_2_12_251_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)31366\u20100"},{"key":"e_1_2_12_252_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_12_253_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201000507"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70229","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.70229","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T12:03:00Z","timestamp":1773748980000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.70229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":252,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/ajh.70229"],"URL":"https:\/\/doi.org\/10.1002\/ajh.70229","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"2026-01-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}